explore -WSS

explore

author：focus 2025-10-03 00:22:15 - browse：2

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Organ aging and disease risk measured by new blood test

WSS

Risky weight loss products often used by teens globally, per study

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Flagship Pioneering launches a new biotech in two countries

Risky weight loss products often used by teens globally, per study

Health and fitness trackers are measuring the wrong things

Diagnostic tests are hitting their mathematical limits

hotspot

explore

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Fetal surgery at risk from Dobbs and new abortion restrictions

Walensky prepares to leave CDC — and Congress — behind

The SUPPORT Act is critical to fighting the opioid crisis

How to save PrEP access — and even expand it

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Drug repurposing or repositioning? The language matters

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Dobbs anniversary: the lost opportunity of abortion as health care

Flagship Pioneering launches a new biotech in two countries

hotspot

JPM 2024: Verve Therapeutics looks to mainstream genome editing

New Medicare drug pricing powers could soon be upended in court

Generative AI mines health records to identify patients’ social needs

New Medicare drug pricing powers could soon be upended in court

Organ aging and disease risk measured by new blood test

Organ aging and disease risk measured by new blood test

knowledge

hotspot

Wikipedia

hotspot